December 26, 2025 Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations ...
December 18, 2025 Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision ...
October 30, 2025 Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care ...
October 14, 2025 Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease ...
September 3, 2025 Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance ...
August 18, 2025 Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt ...
July 9, 2025 Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law ...
June 2, 2025 Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology ...
April 14, 2025 Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products ...
April 7, 2025 Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology ...
February 25, 2025 Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products ...
February 24, 2025 Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company ...
Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations
Celularity Announces Closing of Financing Transactions
Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision
Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease
Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance
Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt
Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law
Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies
Celularity Announces Chief Financial Officer Transition
Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology
Celularity Announces Full Year 2024 Operating and Financial Results
Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products
Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology
Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products
Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company
MASS Coalition Welcomes Trump Order Freezing Skin Substitute LCDs